A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This research is being conducted to determine the biodistribution of radiolabeled amatuximab
in tumor and non-tumor tissues in subjects with mesothelin over expressing cancer including
mesothelioma, pancreatic, ovarian or non small cell lung cancer.